MGMT and central nervous system cancer: In summary, here we have presented MGMT genomic rearrangements not only as a novel mechanism of resistance to TMZ in a subset of gliomas but also, to our knowledge, as a unique genetic alteration never described before in response to other chemotherapeutic agents.